Samuel Grigg

12PUBLICATIONS

8CO-AUTHORS

Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsLiquid biopsiesPredictive and prognostic markersRespiratory diseases

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (12)

Sort by Publication Date:

|Jul 07, 2026

Durable response to salvage gilteritinib, allogeneic stem cell rescue and maintenance therapy in relapsed AML with a <i>FLT3</i> N676K variant.

|Dec 22, 2024

Genomic mechanisms associated with resistance to PDL1-blockade in a patient with mantle cell lymphoma.

Samuel Grigg, Stephen Lade, Georgina Ryland

|Nov 19, 2024

Rates of discordant CD20 status by flow cytometry and immunohistochemistry in B-ALL.

Samuel Grigg, Melissa Ng Liet Hing, Kah Lok Chan

|May 09, 2024

Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high.

Samuel Grigg, Adrian Minson, Elizabeth Prins

|Sep 11, 2019

Angiotensin- neprilysin inhibitors: should we initiate them in hospital for patients with acute decompensated heart failure?

Sam E Grigg

|Jun 12, 2019

Letter: mechanistic target of rapamycin inhibitors-do they impact on recurrence of hepatocellular carcinoma after liver transplantation? Authors' reply.

Sam E Grigg, Gino L Sarri, Paul J Gow

Pageof 2

Frequent Collaborators

Neville Yeomans

Andrew Grigg

Carl Heneghan

Gino L Sarri

Adrian Minson

Melissa Ng Liet Hing

Stephen Lade

Amit Khot

Frequent Collaborators

Neville Yeomans

Andrew Grigg

Carl Heneghan

Gino L Sarri